Tanta University
Tanta, El-Gharbia, 31527, Egypt
Location status: Recruiting
Location contact
Asmaa R Eid, MSc
CONTACT
Jihan M Darwish, MD
SUB_INVESTIGATOR
Najat S Al Shamaa, MD
SUB_INVESTIGATOR
Omnia A El Miseery, MD
SUB_INVESTIGATOR
NCT Number: NCT07515456
The aim of this study is to compare the safety and efficacy of theophylline, sumatriptan, and gabapentin in the treatment of post-dural puncture headache.
Interested in participating?
Request Info21 year–50 year
All sexes
Interventional
Not applicable
Tanta, El-Gharbia, 31527, Egypt
Location status: Recruiting
Asmaa R Eid, MSc
CONTACT
Jihan M Darwish, MD
SUB_INVESTIGATOR
Najat S Al Shamaa, MD
SUB_INVESTIGATOR
Omnia A El Miseery, MD
SUB_INVESTIGATOR
Post-dural puncture headache (PDPH) is a frequent complication of spinal anaesthesia or dural puncture and is an uncomfortable situation for both the patient and the anesthetist.
Theophylline as a form of methyl xanthine, is an adenosine receptor antagonist and can decrease intracranial blood flow and venous enlargement. Evidence shows that intravenous theophylline infusion is a rapid, effective, non-invasive, practical, and low-cost method to treat post-spinal headache.
Sumatriptan is a selective agonist of 5-hydroxytrytamine-like receptors and is used in the treatment of migraine. It has been used in the treatment of PDPH where it may prevent cerebral vasodilation associated with the cerebrospinal fluid (CSF) leak.
Gabapentin is a structural analogue of gamma amino butyric acid; it was used as an anticonvulsant drug for the first time. This drug is now applied in diabetic neuropathy, neuropathic cancer pain and inflammatory injury.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients included in this group will receive oral 150 mg theophylline anhydrous tablet (QuibronT/SR, 300 mg dividose tablet, SmithKline Beecham Egypt L.L.C) every 12 hours.
Patients included in this group will receive oral 25 mg sumatriptan succinate tablet (Sumigran 25, 25 mg tablet, Sigma pharmaceutical industries, Egypt) every 12 hours.
Patients included in this group will receive 200 mg of gabapentin every 12 hours.
Time frame: 24 hours after drug treatment.
Severity of headache will be assessed using numeric rating scale (NRS) score where 0 = no pain, and 10 = worst possible pain.
Time frame: 24 hours after drug treatment.
Post-Dural Puncture Headache (PDPH) duration will be recorded from the occurrence of PDPH till numeric rating scale (NRS) score ≤3.
Time frame: Till the discharge from the hospital (Up to 2 weeks)
Length of hospital stay will be recorded from the hospital admission till discharge.
Time frame: 24 hours after drug treatment.
Treatment-related side effects such as palpitation, dizziness, gastric irritation, nausea/vomiting, diarrhea, warm sensations in the body, tingling sensation, and tightness in the chest, throat, neck, or jaws will be recorded.
Time frame: 24 hours after drug treatment.
Total amount of rescue analgesia consumption will be measured.
Time frame: 24 hours after drug treatment.
Degree of patient satisfaction will be assessed on a 5-point Likert scale patient satisfaction (1, extremely dissatisfied; 2, unsatisfied; 3, neutral; 4, satisfied; 5, extremely satisfied)
Contact information is provided by the study sponsor or research team.
Tanta University
Other
A Comparison Between Safety and Efficacy of Theophylline, Versus Sumatriptan and Gabapentin in The Treatment of Post-Dural Puncture Headache: A Prospective Randomized Double Blinded Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07729449
Brain Diseases, Cardiovascular Diseases
Ordu, Altinordu, Turkey (Türkiye)
View Trial DetailsNCT06824025
Brain Diseases, Central Nervous System Diseases
Minya, Egypt
View Trial DetailsNCT05116930
Brain Diseases, Central Nervous System Diseases
Rochester, Minnesota, United States
View Trial DetailsNCT05804448
Brain Diseases, Central Nervous System Diseases
Jumla, Karnali, Nepal
View Trial Details